News

Capgemini’s strategy now focuses on accelerating physical‑AI deployments through a blend of strategy, engineering, data, AI, operational technology and industry expertise. The company aims to move customers from experimentation to enterprise‑scale deployment, reinforcing its position to lead in the Physical AI Services market.

Full article

Capgemini was named a Market Shaper in the Gartner Emerging Market Quadrant for “Physical AI Services – Established Vendors” and the “Company to Beat” for Physical AI Services. Gartner’s assessment was based on six criteria – technical capabilities, customer implementations, potential customer base, business model, key partnerships and surrounding...

Full article

Overall, Capgemini’s Gartner recognition underscores its global development trajectory in physical AI, while its valuation metrics reveal a significant discount to intrinsic value driven by strong AI and cloud initiatives, tempered by regional revenue and margin risks.

Full article

Bank of America also identified upside in the ITDS segment, citing a networking recovery, data‑infrastructure growth, and high‑performance compute demand tied to AI‑driven investment. The bank noted healthy demand for networking and data infrastructure and improving datacenter connectivity momentum. Following the initiation of coverage, Bel Fuse sh...

Full article

On the same day a Bank of America analyst initiated coverage of Bel Fuse with a Buy rating and a $330 price objective. The rating was supported by the company’s shift toward higher‑margin end markets, notably aerospace and defense, along with portfolio optimisation, improved pricing, and cost discipline. Bank of America highlighted the May 2026 Cla...

Full article

Bel Fuse Inc. (Nasdaq: BELFA/BELFB) announced that preliminary financial results for the second quarter of 2026 will be released after market close on July 29 2026, followed by an earnings conference call on July 30 2026 at 8:30 a.m. ET. The call is expected to cover revenue growth, profitability, and operational efficiency across its aerospace, de...

Full article

The firm’s pipeline continues to move forward with two Phase 3 trials of barzolvolimab, whose topline data are expected later this year. A Biologics License Application (BLA) submission is planned for 2027. The company’s lead investigational candidate has shown promising Phase 2 results and is expanding into indications such as chronic spontaneous...

Full article

Market commentary highlights a 90‑day share‑price gain of 74.56 % and a 30‑day rise of 22.95 %. Analysts argue the stock may still be undervalued, citing a fair‑value estimate above $83.84, though others flag a price‑to‑sales ratio of 12.1x as high relative to peers. The narrative centers on Rubrik’s potential for revenue growth, margin reset, and...

Full article

Rubrik also entered strategic collaborations. It joined Internet2, a consortium of over 500 colleges, universities, and research institutions, to provide backup and cyber‑recovery services tailored for higher‑education environments where 82 % reported cyber threats. Additionally, Rubrik became a member of the Coalition for Health AI (CHAI), alignin...

Full article

In product innovation, Rubrik unveiled an agentic‑first AI platform. The new Rubrik AI introduces “Agentic Mode” and “Agentic Guardrails”, automating reasoning and orchestration across security and data products. This shift aims to cut time to recover from cyber incidents and mitigate risks from malicious or compromised internal AI agents.

Full article